PAA
LOXO

Peregrine Asset Advisers’s Loxo Oncology, Inc LOXO Stock Holding History

Peregrine Asset Advisers’s Portfolio LOXO Stock Details LOXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-56,870
Closed -$4.56M – 101
2017
Q2 		$4.56M Buy
+56,870
New +$3.15M 2.91% 10

Other funds holding LOXO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Peregrine Asset Advisers's LOXO Position: Q3 2017 in Review

Peregrine Asset Advisers sold out of Loxo Oncology, Inc (LOXO) in Q3 2017, closing a stake of 56,870 shares — an estimated $4.56M sold.

Peregrine Asset Advisers first reported a position in LOXO in Q2 2017 and held it in 1 quarter. The position peaked at $4.56M in Q2 2017. 148 funds tracked by Wall St. Rank hold LOXO as of Q3 2017.

  • Peregrine Asset Advisers reported no remaining Loxo Oncology, Inc position as of Q3 2017 after selling out during the quarter.
  • Peregrine Asset Advisers sold 56,870 Loxo Oncology, Inc shares in Q3 2017, an estimated $4.56M.
  • Peregrine Asset Advisers first reported a position in Loxo Oncology, Inc in Q2 2017 and held it in 1 quarter.
  • Peregrine Asset Advisers's Loxo Oncology, Inc position peaked at $4.56M in Q2 2017.
  • 148 funds tracked by Wall St. Rank held Loxo Oncology, Inc as of Q3 2017.

Based on Peregrine Asset Advisers's 13F filing for Q3 2017, filed 9 Nov 2017.